<DOC>
	<DOC>NCT00495521</DOC>
	<brief_summary>The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times daily for 2 weeks followed by 50 milligrams per kilogram twice daily for 2 weeks, will resolve an acute flare of ileocecal Crohn's disease.</brief_summary>
	<brief_title>High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<criteria>Age less than 18 years Crohn's disease predominantly involving the ileum and/or cecum. The diagnosis must have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3 modalities) with at least one confirmatory test having been performed no more than 36 months before entry. The diagnosis must have been confirmed by at least one gastroenterologist. Harvey Bradshaw Index of at least 7 The onset of the acute flare should have been abrupt, declaring itself over 72 hours, and should have started no more than 4 weeks before study entry. Symptoms relating to the flare should not have diminished or started to improve prior to entry. Written informed consent Concomitant corticosteroids, budesonide Corticosteroids within 2 months Cyclosporine, mycophenolate mofetil or experimental drugs during the last three months Maintenance infliximab, or infliximab or other biologics in the preceding 3 months If the severity of the flare has started to decrease spontaneously Coexisting diagnosis of primary sclerosing cholangitis Infectious diarrhea Signs of intestinal obstruction or perforation New fistulization as part of the acute flare or increased activity in chronic fistula(e) as part of the acute flare Hypersensitivity to 4ASA or any components of PASER® Pregnancy or breastfeeding Failure of a woman of childbearing potential to agree to use adequate contraception for the 4 week period of the trial, if sexually active Severe renal or hepatic disease (i.e., more than 3 times upper limit of normal) or a WBC &lt; 3,000 during the preceding three months</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Crohn's</keyword>
	<keyword>Crohn's Disease</keyword>
	<keyword>Acute Flare</keyword>
	<keyword>Mild to Moderate Crohn's Disease</keyword>
	<keyword>Children</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Ileo-cecal</keyword>
	<keyword>Pediatric Crohn's Disease</keyword>
	<keyword>New Onset Crohn's Disease</keyword>
	<keyword>Recently diagnosed Crohn's Disease</keyword>
</DOC>